Nature of the hemopoietic stem cell compartment and its proliferative potential
- PMID: 555689
Nature of the hemopoietic stem cell compartment and its proliferative potential
Abstract
The nature of the hemopoietic stem cell compartment has been the subject of much controversy. Data are presented to support the concept of a 'continuum' model of the stem cell compartment. The important characteristics of this model are that within the continuum there are cells with varying proliferative capacities. As cells move through the compartment, their proliferative capacity becomes more limited, their likelihood to be in cycle increases, and their commitment to a specific differentiated pathway increases. Experiments with busulfan, cyclophosphamide, 5-flurouracil, and BCNU demonstrate defects in proliferative potential of the surviving CFU-S population. These defects persist throughout the life of the animal without any evidence of recovery. The clinical implications of late stem cell failure may be important as a consideration in the use of cytotoxic agents.
Similar articles
-
Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.Exp Hematol. 1993 Jan;21(1):156-62. Exp Hematol. 1993. PMID: 8435103
-
Differential effects of cytotoxic agents on hematopoietic progenitors.Cancer Res. 1981 Jun;41(6):2338-42. Cancer Res. 1981. PMID: 7237432
-
Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs.Exp Hematol. 1993 Jul;21(7):913-21. Exp Hematol. 1993. PMID: 8100536
-
The stem cell continuum: cell cycle, injury, and phenotype lability.Ann N Y Acad Sci. 2007 Jun;1106:20-9. doi: 10.1196/annals.1392.016. Epub 2007 Mar 14. Ann N Y Acad Sci. 2007. PMID: 17360803 Review.
-
The problem of permanent bone marrow damage after cytotoxic drug treatment.Oncology. 1984;41(3):180-4. doi: 10.1159/000225819. Oncology. 1984. PMID: 6374556 Review.
Cited by
-
Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients.Blood. 2009 May 21;113(21):5094-103. doi: 10.1182/blood-2008-09-176412. Epub 2009 Mar 31. Blood. 2009. PMID: 19336761 Free PMC article.
-
Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.Br J Cancer. 1983 Sep;48(3):329-34. doi: 10.1038/bjc.1983.196. Br J Cancer. 1983. PMID: 6351883 Free PMC article.
-
Tolerance of hemopoiesis for repeated cytotoxic drug therapy.Blut. 1979 Oct;39(4):237-44. doi: 10.1007/BF01013216. Blut. 1979. PMID: 497405 No abstract available.
-
Mechanistic models for myelosuppression.Invest New Drugs. 2003 May;21(2):183-94. doi: 10.1023/a:1023573429626. Invest New Drugs. 2003. PMID: 12889739 Review.
-
Partitioning of bone marrow into stem cell regulatory domains.Proc Natl Acad Sci U S A. 1982 Feb;79(3):840-4. doi: 10.1073/pnas.79.3.840. Proc Natl Acad Sci U S A. 1982. PMID: 6950430 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials